NASDAQ:GANX Gain Therapeutics (GANX) Stock Price, News & Analysis $1.99 +0.11 (+5.85%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$2.01 +0.02 (+1.21%) As of 08/29/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Gain Therapeutics Stock (NASDAQ:GANX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Gain Therapeutics alerts:Sign Up Key Stats Today's Range$1.89▼$2.0250-Day Range$1.44▼$1.9952-Week Range$0.95▼$3.19Volume599,362 shsAverage Volume372,770 shsMarket Capitalization$71.54 millionP/E RatioN/ADividend YieldN/APrice Target$7.80Consensus RatingBuy Company Overview Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland. Read More Gain Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks42nd Percentile Overall ScoreGANX MarketRank™: Gain Therapeutics scored higher than 42% of companies evaluated by MarketBeat, and ranked 669th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingGain Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageGain Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Gain Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Gain Therapeutics are expected to grow in the coming year, from ($1.00) to ($0.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Gain Therapeutics is -3.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Gain Therapeutics is -3.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGain Therapeutics has a P/B Ratio of 19.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Gain Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.74% of the float of Gain Therapeutics has been sold short.Short Interest Ratio / Days to CoverGain Therapeutics has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Gain Therapeutics has recently increased by 22.23%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGain Therapeutics does not currently pay a dividend.Dividend GrowthGain Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.74% of the float of Gain Therapeutics has been sold short.Short Interest Ratio / Days to CoverGain Therapeutics has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Gain Therapeutics has recently increased by 22.23%, indicating that investor sentiment is decreasing significantly. News and Social Media2.2 / 5News Sentiment0.03 News SentimentGain Therapeutics has a news sentiment score of 0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.05 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Gain Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for GANX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows2 people have added Gain Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Gain Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.18% of the stock of Gain Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 11.97% of the stock of Gain Therapeutics is held by institutions.Read more about Gain Therapeutics' insider trading history. Receive GANX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gain Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GANX Stock News HeadlinesGain Therapeutics, Inc. (NASDAQ:GANX) Given Consensus Rating of "Buy" by BrokeragesAugust 30 at 3:49 AM | americanbankingnews.comHC Wainwright Cuts Earnings Estimates for Gain TherapeuticsAugust 28 at 2:23 AM | americanbankingnews.comHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking and savings account… With this better, more technologically advanced dollar. President Trump himself called it a "big innovation"… And said that this new form of currency represents "American brilliance at its best."August 30 at 2:00 AM | Brownstone Research (Ad)Gain Therapeutics Reports Q2 2025 Financial ResultsAugust 21, 2025 | tipranks.comGain Therapeutics price target lowered to $6 from $7 at Roth CapitalAugust 13, 2025 | msn.comGain Therapeutics reports Q2 EPS (19c), consensus (17c)August 12, 2025 | msn.comGain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate UpdateAugust 12, 2025 | globenewswire.comGain Therapeutics to Present at BTIG Annual Virtual Biotechnology ConferenceJuly 24, 2025 | globenewswire.comSee More Headlines GANX Stock Analysis - Frequently Asked Questions How have GANX shares performed this year? Gain Therapeutics' stock was trading at $2.16 at the start of the year. Since then, GANX stock has decreased by 7.9% and is now trading at $1.99. How were Gain Therapeutics' earnings last quarter? Gain Therapeutics, Inc. (NASDAQ:GANX) released its quarterly earnings data on Tuesday, August, 12th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.17) by $0.02. When did Gain Therapeutics IPO? Gain Therapeutics (GANX) raised $40 million in an initial public offering (IPO) on Thursday, March 18th 2021. The company issued 3,600,000 shares at $10.00-$12.00 per share. BTIG and Oppenheimer & Co,. acted as the underwriters for the IPO and National Securities Corp. was co-manager. Who are Gain Therapeutics' major shareholders? Gain Therapeutics' top institutional investors include Geode Capital Management LLC (0.97%) and Marshall Wace LLP (0.92%). Insiders that own company stock include Khalid Islam, Jeffrey Scott Riley, Gene Mack and Matthias Alder. View institutional ownership trends. How do I buy shares of Gain Therapeutics? Shares of GANX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Gain Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Gain Therapeutics investors own include PayPal (PYPL), Pfizer (PFE), SEA (SE), Taiwan Semiconductor Manufacturing (TSM), ZIM Integrated Shipping Services (ZIM), ADC Therapeutics (ADCT) and Avino Silver & Gold Mines (ASM). Company Calendar Last Earnings8/12/2025Today8/30/2025Next Earnings (Estimated)11/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GANX CIK1819411 Webwww.gaintherapeutics.com Phone301-500-1556FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Price Target for Gain Therapeutics$7.80 High Price Target$12.00 Low Price Target$6.00 Potential Upside/Downside+292.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$20.41 million Net MarginsN/A Pretax MarginN/A Return on Equity-289.10% Return on Assets-155.11% Debt Debt-to-Equity Ratio0.09 Current Ratio1.79 Quick Ratio1.79 Sales & Book Value Annual Sales$50 thousand Price / Sales1,430.81 Cash FlowN/A Price / Cash FlowN/A Book Value$0.10 per share Price / Book19.90Miscellaneous Outstanding Shares35,950,000Free Float33,368,000Market Cap$71.54 million OptionableOptionable Beta0.10 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:GANX) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMy NEXT $1 Trillion PredictionJames Altucher is making his next trillion-dollar prediction — and this time, it’s not Apple. He believes Elon...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gain Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gain Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.